MCID: KDN017
MIFTS: 65

Kidney Cancer malady

Categories: Cancer diseases, Nephrological diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Kidney Cancer

Aliases & Descriptions for Kidney Cancer:

Name: Kidney Cancer 12 41 14
Renal Carcinoma 12 14 69
Renal Cancer 12 52 14
Kidney Carcinoma 12 29
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 69
Malignant Tumour of Kidney 12
Renal Cell Carcinoma 69
Carcinoma of Kidney 12
Kidney Neoplasms 42
Kidney Neoplasm 69

Classifications:



Summaries for Kidney Cancer

MedlinePlus : 41 you have two kidneys. they are fist-sized organs on either side of your backbone above your waist. the tubes inside filter and clean your blood, taking out waste products and making urine. kidney cancer forms in the lining of tiny tubes inside your kidneys. kidney cancer becomes more likely as you age. risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. you may have no symptoms at first. they may appear as the cancer grows. see your health care provider if you notice blood in your urine a lump in your abdomen weight loss for no reason pain in your side that does not go away loss of appetite tests to diagnose kidney cancer include blood, urine, and imaging tests. you may also have a biopsy. treatment depends on your age, your overall health and how advanced the cancer is. it might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary : Kidney Cancer, also known as renal carcinoma, is related to childhood multilocular cystic kidney neoplasm and kidney cancer, childhood, and has symptoms including flank pain An important gene associated with Kidney Cancer is IL2 (Interleukin 2), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and testes, and related phenotypes are cardiovascular system and cellular

Disease Ontology : 12 A kidney cancer that derives from the lining of the proximal convoluted tubule (the very small tubes in the kidney that filter the blood and remove waste products).

Wikipedia : 71 Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the... more...

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Benign Neoplasm Kidney Carcinoma in Situ
Renal Carcinoma, Familial

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
id Related Disease Score Top Affiliating Genes
1 childhood multilocular cystic kidney neoplasm 11.8
2 kidney cancer, childhood 11.7
3 kidney carcinoma in situ 11.7
4 renal carcinoma, familial 11.7
5 renal cell carcinoma, papillary 11.3
6 renal cell carcinoma 11.2
7 leiomyomatosis and renal cell cancer 11.1
8 collecting duct carcinoma 10.8
9 wilms tumor susceptibility-5 10.7
10 birt-hogg-dube syndrome 10.7
11 rhabdoid cancer 10.7
12 kidney clear cell sarcoma 10.6
13 perlman syndrome 10.6
14 von hippel-lindau syndrome 10.6
15 cowden disease 10.6
16 denys-drash syndrome 10.6
17 kidney hemangiopericytoma 10.6
18 chromophobe renal cell carcinoma 10.6
19 transitional cell carcinoma 10.6
20 kidney sarcoma 10.6
21 angiomatosis 10.6
22 localized anterior staphyloma 10.4 IFNA1 TP53
23 gtp cyclohydrolase 1-deficient dopa-responsive dystonia 10.4 FH HIF1A VHL
24 thyrotoxic periodic paralysis 2 10.3 FH FLCN MTOR
25 pharc syndrome 10.3 IL2 MTOR VEGFA
26 polycythemia 10.3 FLCN MTOR TSC2
27 multinodular goiter 10.3 IL2 MTOR VEGFA
28 clear cell adenofibroma 10.3 IFNA2 TP53
29 pelger-huet anomaly 10.3 FH HIF1A SDHB
30 gallbladder cancer 10.3 FLCN MTOR TSC2
31 complement deficiency 10.3 FH FLCN MET
32 cowden syndrome 3 10.3 FH SDHB VHL
33 acute posterior multifocal placoid pigment epitheliopathy 10.3 HIF1A VEGFA VHL
34 central cervical cord syndrome 10.3 IFNA2 TSC2 VHL
35 isolated methylmalonic acidemia 10.3 FH SDHB VHL
36 anterior foramen magnum meningioma 10.3 IFNA1 IFNA2 IL2 TP53
37 lipoadenoma 10.3 FH FLCN RASSF1
38 catastrophic antiphospholipid syndrome 10.3 SDHB VHL
39 central nervous system leiomyosarcoma 10.3 CA9 HIF1A VEGFA VHL
40 urinary bladder posterior wall cancer 10.3 FGF2 HIF1A VEGFA
41 glucose-6-phosphate translocase deficiency 10.3 MET MTOR TP53 VEGFA
42 congenital disorder of glycosylation, type iq 10.3 FGF2 IFNA1 IFNA2
43 zollinger-ellison syndrome 10.3 FH SDHB VHL
44 oppositional defiant disorder 10.3 FGF2 HIF1A VEGFA
45 placenta praevia 10.3 IFNA2 RASSF1 TP53 VEGFA
46 generalized eruptive keratoacanthoma 10.3 CA9 PBRM1 VHL
47 metagonimiasis 10.3 FGF2 MET TP53 VEGFA
48 non-distal monosomy 10q 10.2 FHIT MET TP53 VEGFA
49 glucosephosphate isomerase deficiency 10.2 FGF2 IL2 MTOR TP53 VEGFA
50 grade iii astrocytoma 10.2 FGF2 TP53 TSC2 VEGFA

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:


flank pain

MGI Mouse Phenotypes related to Kidney Cancer:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 MTOR PBRM1 RASSF1 SDHB TP53 TSC2
2 cellular MP:0005384 10.37 CD274 FGF2 FH FLCN HIF1A IL2
3 homeostasis/metabolism MP:0005376 10.37 CD274 FGF2 FH FHIT FLCN HIF1A
4 mortality/aging MP:0010768 10.33 CA9 CD274 FGF2 FH FHIT FLCN
5 hematopoietic system MP:0005397 10.32 TSC2 VEGFA VHL CA9 CD274 FGF2
6 immune system MP:0005387 10.32 CA9 CD274 FHIT FLCN HIF1A IL2
7 endocrine/exocrine gland MP:0005379 10.3 TSC2 VEGFA VHL CA9 HIF1A IL2
8 digestive/alimentary MP:0005381 10.2 IL2 MET RASSF1 TP53 VEGFA VHL
9 embryo MP:0005380 10.19 FLCN HIF1A MET MTOR PBRM1 TP53
10 neoplasm MP:0002006 10.15 RASSF1 SDHB TP53 TSC2 VEGFA VHL
11 liver/biliary system MP:0005370 10.13 HIF1A IL2 MET PBRM1 PLIN2 RASSF1
12 integument MP:0010771 10.06 CD274 FHIT HIF1A PLIN2 TP53 TSC2
13 normal MP:0002873 9.91 HIF1A MET MTOR RASSF1 SDHB TP53
14 no phenotypic analysis MP:0003012 9.87 CD274 IL2 MET MTOR SDHB TP53
15 renal/urinary system MP:0005367 9.81 TSC2 VEGFA VHL FH FLCN HIF1A
16 respiratory system MP:0005388 9.5 HIF1A IL2 MET MTOR PBRM1 TP53
17 vision/eye MP:0005391 9.23 TP53 VEGFA VHL FGF2 HIF1A IL2

Drugs & Therapeutics for Kidney Cancer

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
2
Avastin 17 46 BEVACIZUMAB Genentech Approved July 2009
3
Inlyta 17 46 AXITINIB Pfizer Approved January 2012
4
Nexavar 17 46 SORAFENIB TOSYLATE Bayer/Onyx Approved December 2005
5
Proleukin 17 46 ALDESLEUKIN Chiron Approved January 1998
6
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
7
Torisel 17 46 TEMSIROLIMUS Wyeth Approved May 2007
8
Votrient 17 46 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline Approved April 2012/ Approved October of 2009

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1167)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Pioglitazone Approved, Investigational Phase 4,Phase 2,Early Phase 1 111025-46-8 4829
4
Simvastatin Approved Phase 4,Phase 1 79902-63-9 54454
5
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
6
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
8
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
9
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
10
Rifampin Approved Phase 4,Phase 1,Early Phase 1 13292-46-1 5458213 5381226
11
Loperamide Approved Phase 4,Phase 1,Phase 2 53179-11-6 3955
12
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-43-4 5816
14
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
15
Iron Approved Phase 4,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
16
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
17
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
18
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2 147127-20-6 464205
19
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
20
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
21
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 1 169590-42-5 2662
22
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
23
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
24
Lisinopril Approved, Investigational Phase 4 83915-83-7 5362119
25
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
26
Amlodipine Approved Phase 4,Phase 2 88150-42-9 2162
27
Aminolevulinic acid Approved Phase 4,Phase 3 106-60-5 137
28
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
29
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
30
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
31
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 174722-31-7 10201696
32
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
33
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
34
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
35
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
37
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
38
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
39
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
40
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
41
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 82419-36-1 4583
42
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
43
Daclizumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 152923-56-3
44
Vancomycin Approved Phase 4,Phase 2,Phase 3,Early Phase 1 1404-90-6 441141 14969
45
lanreotide Approved Phase 4,Phase 2,Phase 3 108736-35-2
46
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
47
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
48
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
49
Meropenem Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 119478-56-7 64778 441130
50
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 3602)
id Name Status NCT ID Phase
1 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
2 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
3 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
4 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
5 Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation Unknown status NCT00903188 Phase 4
6 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4
7 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4
8 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
9 Validation of an Adjusted Dosing Algorithm of Carboplatin Unknown status NCT02103244 Phase 4
10 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4
11 Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function Unknown status NCT00541814 Phase 4
12 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
13 A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4
14 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4
15 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
16 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
17 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
18 Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension Unknown status NCT02184858 Phase 4
19 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
20 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
21 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4
22 Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin Unknown status NCT02443064 Phase 4
23 Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4
24 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4
25 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4
26 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
27 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4
28 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4
29 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4
30 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma Completed NCT00460798 Phase 4
31 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
32 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4
33 Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Completed NCT01339962 Phase 4
34 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4
35 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4
36 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
37 Sorafenib in Elderly mRCC Completed NCT01728948 Phase 4
38 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4
39 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
40 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4
41 Chlorhydrate of Ropivacaine and Breast Cancer Surgery Completed NCT00370240 Phase 4
42 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4
43 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4
44 Efficacy of Pentoxifylline on Chronic Kidney Disease Completed NCT00155246 Phase 4
45 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4
46 Hydroxyethyl Starch and Renal Function After Radical Prostatectomy Completed NCT01486563 Phase 4
47 Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors Completed NCT01653041 Phase 4
48 Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Completed NCT00375752 Phase 4
49 Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer Completed NCT02321202 Phase 4
50 The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis Completed NCT01753154 Phase 4

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

id Genetic test Affiliating Genes
1 Renal Neoplasm 29

Anatomical Context for Kidney Cancer

MalaCards organs/tissues related to Kidney Cancer:

39
Kidney, Endothelial, Testes, Breast, Prostate, Lung, Thyroid

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 674)
id Title Authors Year
1
Incorporating New Systemic Therapies in Kidney Cancer Treatment. ( 28515249 )
2017
2
Mutation screening of ACKR3 and COPS8 in kidney cancer cases from the CONFIRM study. ( 28063109 )
2017
3
Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations. ( 28358873 )
2017
4
Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment. ( 28459940 )
2017
5
Kidney cancer: Tracking and therapy selection using ctDNA. ( 28467397 )
2017
6
Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. ( 28423633 )
2017
7
Sunitinib in kidney cancer: 10 years of experience and development. ( 27967249 )
2017
8
Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based Study. ( 28314541 )
2017
9
Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. ( 28085177 )
2017
10
Setting Research Priorities for Kidney Cancer. ( 28495043 )
2017
11
A comprehensive analysis of cancer-driving mutations and genes in kidney cancer. ( 28454375 )
2017
12
Kidney cancer: Path to progression: intracrine signalling in RCC. ( 28322261 )
2017
13
Basic/Translational Science Survey Section: Kidney Cancer. ( 28340689 )
2017
14
Synergistic Activity for Natural and Synthetic Inhibitors of Angiogenesis Induced by Murine Sarcoma L-1 and Human Kidney Cancer Cells. ( 28456932 )
2017
15
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. ( 28061437 )
2017
16
Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. ( 28503238 )
2017
17
Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. ( 27992843 )
2017
18
Hereditary Kidney Cancer Syndromes and Surgical Management of the Small RenalA Mass. ( 28411908 )
2017
19
Kidney cancer: Targeting metabolism in RCC. ( 28420887 )
2017
20
Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. ( 28005615 )
2017
21
Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy. ( 27888385 )
2017
22
Potential Pathogenesis and Biomarkers of Kidney Cancer-Related Stroke. ( 28505148 )
2017
23
Adjuvant therapy for high-risk localized kidney cancer- emerging evidence and future clinical trials. ( 28479237 )
2017
24
Second Primary Cancer Risk Among Kidney Cancer Patients in Korea: A Population-Based Cohort Study. ( 28421722 )
2017
25
Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors. ( 28408240 )
2017
26
Basic/Translational Science Survey: Kidney Cancer. ( 28340690 )
2017
27
International cancer seminars: a focus on kidney cancer. ( 27130845 )
2016
28
Kidney cancer: Papillary features predict survival in ncRCC. ( 27644932 )
2016
29
Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics. ( 28031562 )
2016
30
Kidney cancer: Exosome transmission of sunitinib resistance. ( 27162048 )
2016
31
Statin use and kidney cancer outcomes: A propensity score analysis. ( 27427224 )
2016
32
Relation between kidney cancer and Soil leads in Isfahan Province, Iran between 2007 and 2009. ( 27461639 )
2016
33
The regulatory role of nickel on H3K27 demethylase JMJD3 in kidney cancer cells. ( 25427687 )
2016
34
Kidney cancer. ( 27626782 )
2016
35
Kidney cancer: OCT2 demethylation cracks open oxaliplatin resistance. ( 27498955 )
2016
36
Kidney Cancer News. ( 27930624 )
2016
37
Obesity and Kidney Cancer. ( 27909903 )
2016
38
Kidney cancer: Sunitinib resistance is futile. ( 27618771 )
2016
39
Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer. ( 27592258 )
2016
40
Significant association of catechol-O-methyltransferase Val158Met polymorphism with bladder cancer instead of prostate and kidney cancer. ( 27055785 )
2016
41
Patient Function and the Value of Surgical Care for Kidney Cancer. ( 27986531 )
2016
42
Patient function, long-term survival, and use of surgery in patients with kidney cancer. ( 27518165 )
2016
43
Birt-Hogg-DubAc syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome. ( 26608100 )
2016
44
Psychological Disorders and Psychosocial Resources of Patients with Newly Diagnosed Bladder and Kidney Cancer: A Cross-Sectional Study. ( 27191964 )
2016
45
The science of checkpoint inhibition in kidney cancer. ( 27166601 )
2016
46
Highlights in kidney cancer from the 2016 American Society of Clinical Oncology Annual Meeting. ( 27487102 )
2016
47
Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer. ( 27884597 )
2016
48
Non-Destructive Diagnosis of Kidney Cancer on 18- Gauge Core Needle Renal Biopsy Using Dual-Color Fluorescence Structured Illumination Microscopy. ( 27597632 )
2016
49
Clearing the Air: Summarizing the Smoking-related Relative Risks of Bladder and Kidney Cancer. ( 27130147 )
2016
50
Skin manifestations associated with kidney cancer. ( 27178696 )
2016

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

6 (show all 33)
id Gene Variation Type Significance SNP ID Assembly Location
1 VHL NM_000551.3(VHL): c.548C> A (p.Ser183Ter) single nucleotide variant Pathogenic rs5030823 GRCh37 Chromosome 3, 10191555: 10191555
2 VHL NM_000551.3(VHL): c.481C> T (p.Arg161Ter) single nucleotide variant Pathogenic/Likely pathogenic rs5030818 GRCh37 Chromosome 3, 10191488: 10191488
3 VHL NM_000551.3(VHL): c.499C> T (p.Arg167Trp) single nucleotide variant Pathogenic/Likely pathogenic rs5030820 GRCh37 Chromosome 3, 10191506: 10191506
4 ATM ATM, IVS61DS, 2-BP INS, +2TA insertion Pathogenic
5 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
7 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
8 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
9 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
10 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
11 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
12 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
13 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh37 Chromosome 7, 116423414: 116423414
14 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913243 GRCh37 Chromosome 7, 116417464: 116417464
15 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
16 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
17 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
18 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
19 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
20 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh37 Chromosome 17, 7578508: 7578508
21 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
22 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
23 MTOR NM_004958.3(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
24 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
25 MTOR NM_004958.3(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic/Likely pathogenic rs786205165 GRCh37 Chromosome 1, 11217230: 11217230
26 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
27 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
28 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
29 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
30 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
31 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
32 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
33 PTEN NM_000314.6(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905

Cosmic variations for Kidney Cancer:

9 (show all 21)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 17
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 17
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 17
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 17
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 17
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 17
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 17
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 17
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 17
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 17
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 17
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 17
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 17
14 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.292T>G p.Y98D 16
15 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 16
16 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 16
17 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.500G>A p.R167Q 16
18 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 16
19 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 16
20 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 16
21 COSM52899 PBRM1